Mass Tort brief
UK Motor Finance Class Actions, Infant Formula Settlements, and Mass Tort Rule Changes
Court rulings clear aggregated motor finance suits, Abbott settles formula cases while Reckitt faces federal trial, and the UK Supreme Court enforces GLO binding rules.
Mass Tort
The Court of Appeal's ruling clears group lawsuits against motor finance lenders — exposing UK banks to court liabilities far beyond the regulator's £7.5B compensation scheme.
BackgroundThe Financial Conduct Authority established a £7.5B redress scheme to compensate motorists for secret discretionary commission arrangements on car loans. Major lenders including Lloyds and Barclays are challenging the scheme's legal framework in court.
- The Court of Appeal decision enables law firms to aggregate Consumer Credit Act claims directly in court, bypassing long administrative delays.
- Judges confirmed drivers can pursue 100% compensation through formal lawsuits without waiting for the Financial Conduct Authority scheme payouts.
- Three major UK motor finance lenders filed legal petitions challenging the FCA redress model, deepening structural friction between banks and regulators.
Mass Tort
Abbott's $670M settlement sets a clear valuation benchmark for formula litigation — piling financial pressure on Reckitt as its first federal trial gets underway.
BackgroundOver 12,000 lawsuits allege specialized premature infant formulas produced by Abbott and Reckitt cause fatal necrotizing enterocolitis in preterm infants. State trials previously produced multi-hundred-million-dollar jury verdicts against both manufacturers, spooking healthcare investors.
- Abbott's $670 million deal resolves roughly 2,000 claims, effectively wiping out a contentious $495 million Missouri state court verdict.
- Reckitt Benckiser's Mead Johnson division entered its first federal bellwether trial over Enfamil Premature formula in late August 2026.
- London investors remain focused on Reckitt's legal reserves as federal court outcomes establish baseline settlement valuations for remaining claims.
Mass Tort
GSK's distribution of $2.2B in Zantac settlements resolves its primary mass tort overhang — restoring market confidence in the British drugmaker's pipeline.
BackgroundGSK, Sanofi, and Pfizer faced tens of thousands of claims alleging heartburn drug Zantac contained carcinogenic degradation products. Comprehensive settlement packages negotiated in 2024 and 2025 aimed to clear massive state litigation backlogs.
- Individual settlement payouts range from $100,000 to $500,000 based on claimant diagnosis, exposure length, and dosage history.
- Settlement distributions are scheduled to conclude by late 2026, eliminating a primary valuation overhang for GSK's London-listed shares.
- Remaining state trials continue in California and Illinois against co-defendants while federal appeals courts review disputed scientific evidence.
Mass Tort
The Supreme Court's ruling restricts judges from reopening group litigation outcomes — giving corporate defendants crucial binding certainty in UK class actions.
BackgroundGroup Litigation Orders permit English courts to manage thousands of individual claims presenting shared legal issues by selecting test cases. Previous civil procedure rules left ambiguity regarding when non-test claimants could be unbound from initial test outcomes.
- Justices ruled High Court judges cannot routinely set aside test judgments unless statutory law changes render the original ruling invalid.
- Legal practitioners hailed the decision as crucial operational guidance for managing complex product liability and commercial group actions in London.
- The precedent gives corporate defendants greater certainty when settling early test cases, reducing multi-year litigation risks across UK group claims.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
